natgillin/translations-raw huggingface dataset:
Administration of live vaccines (e.g. BCG vaccine) to infants exposed to Cyltezo in utero is not recommended for 5 months following the mother's last Cyltezo injection during pregnancy. 
Uporaba živih cepiv (npr. BCG cepiva) pri dojenčkih, ki so bili izpostavljeni zdravilu Cyltezo in utero, ni priporočljiva 5 mesecev po zadnji injekciji zdravila Cyltezo, ki jo je mati prejela med nosečnostjo.
The safety and efficacy of adalimumab were assessed in over 1500 patients with moderately to severely active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450) in randomised, double-blind, placebo-controlled studies. 
Varnost in učinkovitost adalimumaba so ocenili pri več kot 1.500 bolnikih z zmerno do zelo aktivno Crohnovo boleznijo (indeks aktivnosti Crohnove bolezni [CDAI] ≥ 220 in ≤ 450) v randomiziranih, dvojno slepih, s placebom kontroliranih študijah.
After two further weeks, continue with a dosage of 40 mg every week or 80 mg every other week, as prescribed by your doctor. 
Čez nadaljnja dva tedna nadaljujte z odmerkom 40 mg vsak teden ali 80 mg vsak drugi teden, kot vam bo predpisal zdravnik.
• Inspect Cyltezo pen, medication and expiration date. 
• Preverite peresnik zdravila Cyltezo, zdravilo in datum izteka roka uporabnosti.
The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the percent of patients who achieved an ACR 20 response at week 24 or 26. 
Primarni opazovani dogodek v študijah revmatoidnega artritisa I, II in III ter sekundarni opazovani dogodek v študiji revmatoidnega artritisa IV je bil odstotek bolnikov, ki so po 24 oz. 26 tednih dosegli odziv 20 po ACR.
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Cyltezo and is positive for antibodies against double-stranded DNA, further treatment with Cyltezo should not be given (see section 
Če se bolniku po zdravljenju z zdravilom Cyltezo pojavijo simptomi, ki nakazujejo lupusu podobni sindrom, in ima pozitivna protitelesa proti dvojnoverižni DNA, zdravljenja z zdravilom Cyltezo ne sme nadaljevati
After 12 weeks of therapy, patients who had received adalimumab in Period A were re-randomised in Period B to 1 of 3 treatment groups (adalimumab 40 mg every week, adalimumab 40 mg every other week, or placebo from week 12 to week 35). 
Po 12. tednih terapije so bolnike, ki so prejemali adalimumab v obdobju A, ponovno randomizirali v obdobju B v eno izmed treh skupin zdravljenja (adalimumab 40 mg vsak teden, adalimumab 40 mg vsak drugi teden ali placebo od 12. do 35. tedna).
Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric 
Kaplan-Meier-jeve krivulje povzemajo čas do neuspeha zdravljenja v študiji uveitisa pri pediatričnih bolnikih
The adjusted OR (accounting for baseline differences) was 1.10 (95 % CI 0.45-2.73) with RA and CD combined. 
Prilagojeno razmerje obetov (z ozirom na izhodiščne razlike) je bilo 1,10 (95 % interval zaupanja 0,45-2,73) z RA in CB skupaj.
Adalimumab treated patients had significantly greater improvement at week 12 which was maintained through week 24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL). 
Bolniki, ki so dobivali adalimumab, so imeli po 12 tednih značilno večje izboljšanje (ki se je ohranilo do 24. tedna) SF36 in Vprašalnik o kakovosti življenja pri ankilozirajočem spondilitisu (ASQoL, Ankylosing Spondylitis Quality of Life Questionnaire).
Alternatively, if a patient has stopped Cyltezo and signs and symptoms of disease recur, Cyltezo may be readministered. 
Če bolnik neha uporabljati zdravilo Cyltezo, pa se znaki in simptomi bolezni ponovijo, je mogoče zdravilo Cyltezo znova uvesti.
Once removed from the refrigerator for room temperature storage, the pen must be used within 14 days or discarded, even if it is returned to the refrigerator. 
Ko ga enkrat, namesto v hladilniku, shranjujete pri sobni temperaturi, morate injekcijski peresnik porabiti v 14 dneh ali pa jo zavreči, tudi če jo vrnete v hladilnik.
Cyltezo is a biosimilar medicinal product. 
Zdravilo Cyltezo je podobno biološko zdravilo.
Among patients with baseline HS-related skin pain assessment ≥ 3, based on Numeric Rating Scale 0 - 10; 0 = no skin pain, 10 = skin pain as bad as you can imagine 
Med bolniki z izhodiščnim rezultatom 3 ali več pri ocenjevanju bolečine, povezane s hidradenitis suppurativa, po numerični ocenjevalni lestvici od 0 do 10; 0 = brez bolečin na koži, 10 = najhujša možna bolečina na koži.
* p value for Standard Dose versus Low Dose comparison. 
* p vrednost za primerjavo standardnega odmerka v primerjavi z majhnim odmerkom
A greater proportion of patients on adalimumab had no disease flare during the double-blind period, when compared with those on placebo (70.4 % vs. 47.1 %, p < 0.001) (Figure 1). 
Pri večjem deležu bolnikov, ki so prejemali adalimumab, v dvojno slepem obdobju ni prišlo do ponovnega zagona bolezni v primerjavi s tistimi, ki so prejemali placebo (70,4 % v primerjavi s 47,1 %, p < 0,001) (slika 1).
Cyltezo can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents (sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), corticosteroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs). 
Zdravilo Cyltezo se lahko uporablja skupaj z metotreksatom ali nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (sulfasalazinom, hidroksiklorokinom, leflunomidom in pripravki zlata za injiciranje), kortikosteroidi in zdravili proti bolečinam, vključno z nesteroidnimi protivnetnimi zdravili.
In patients with at least a partial response to adalimumab 40 mg weekly at week 12, the HiSCR rate at week 36 was higher in patients who continued weekly adalimumab than in patients in whom dosing frequency was reduced to every other week, or in whom treatment was withdrawn (see Table 22). 
Pri bolnikih z vsaj delnim odzivom na adalimumab v odmerku 40 mg vsak teden v 12. tednu, je bila stopnja kliničnega odziva (HiSCR) v 36. tednu višja pri bolnikih, ki so nadaljevali zdravljenje z adalimumabom vsak teden kot pri bolnikih, pri katerih so pogostnost odmerjanja zmanjšali na vsak drugi teden, ali pri katerih je bilo zdravljenje ukinjeno (glejte preglednico 22).
Vision related effects were not numerically in favour of adalimumab for colour vision in Study UVI and for colour vision, peripheral vision 
Učinki povezani z vidom niso bili v korist adalimumaba v primeru barvnega vida v študiji UV I in v primeru barvnega vida, perifernega vida in vida na blizu v študiji UV II.
Ped ACR 30/50/70 responses week 48 significantly greater than those of placebo treated patients p = 0.015 
Odzivi "Ped ACR" 30/50/70 so bili 48. teden značilno večji kot pri bolnikih, ki so dobivali placebo
All p-values are pairwise comparisons of proportions for adalimumab versus placebo 
Vse vrednosti p so za parne primerjave deležev med adalimumabom in placebom.
The safety of adalimumab in paediatric patients with plaque psoriasis has been assessed for a mean of 13 months. 
Varnost adalimumaba pri pediatričnih bolnikih s psoriazo v plakih je bila ocenjena za povprečno
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
On rare occasions, a specific and severe type of lymphoma has been observed in patients taking adalimumab. 
V redkih primerih so pri bolnikih, ki so dobivali adalimumab, opazili specifično in resno obliko limfoma.
Subjects (n = 215, 54.7 %) who failed to achieve ASAS 20 at weeks 12, or 16 or 20 received early escape open-label adalimumab 40 mg every other week subcutaneously and were subsequently treated as non-responders in the double-blind statistical analyses. 
Preiskovanci (n = 215, 54,7 %), ki 12. ali 16. ali 20. teden niso dosegli ASAS 20, so začeli v predčasni odprti fazi dobivati 40 mg adalimumaba vsak drugi teden subkutano, v poznejših statističnih analizah dvojno slepe faza pa so bili obravnavani
Efficacy Responses in Placebo-Controlled AS Study - Study I Reduction of Signs and Symptoms 
Preglednica 13: Odzivi učinkovitosti v študiji pri ankilozirajočem spondilitisu, kontrolirani s placebom - študija I Zmanjšanje znakov in simptomov
The other ingredients are sodium acetate trihydrate, glacial acetic acid, trehalose dihydrate, polysorbate 80 
Druge sestavine zdravila so natrijev acetat trihidrat, ledocetna kislina, trehaloza dihidrat, polisorbat 80
When needed (for example when you are travelling), a single Cyltezo pre-filled syringe may be stored at room temperature (up to 25°C) for a maximum period of 14 days - be sure to protect it from light. 
Če je potrebno (na primer kadar potujete), lahko posamezni napolnjeni injekcijski peresnik zdravila Cyltezo hranite pri sobni temperaturi (do 25 ºC) za največ do 14 dni - zagotovite, da bo zaščitena pred svetlobo.
Taking these results into consideration, Cyltezo is recommended for use in combination with MTX and for use as monotherapy in patients for whom MTX use is not appropriate (see section 4.2). 
Z upoštevanjem teh ugotovitev je zdravila Cyltezo priporočljivo uporabljati v kombinaciji z metotreksatom, kot monoterapijo pa pri bolnikih, za katere uporaba metotreksata ni primerna (glejte
A total of 76.5 % (218/285) of patients who entered the retreatment period had a response of PGA “clear” or “minimal” after 16 weeks of retreatment, irrespective of whether they relapsed during withdrawal (69.1 % [123/178] and 88.8 % [95/107] for patients who relapsed and who did not relapse during the withdrawal period, respectively). 
Od bolnikov, deležnih ponovnega zdravljenja, jih je skupno 76,5 % (218/285) po 16 tednih ponovnega zdravljenja imelo odziv PGA "čisto" ali "minimalno", ne glede na to, ali je med prenehanjem uporabe prišlo do relapsa (69,1 % [123/178] bolnikov, pri katerih je med prenehanjem uporabe prišlo do relapsa, in 88,8 % [95/107] tistih, pri katerih ni prišlo do relapsa).
Ps Study II (CHAMPION) - Efficacy Results at 16 Weeks MTX N = 110 n (%) 
Preglednica 18: Študija pri psoriazi II (CHAMPION) - rezultati učinkovitosti po 16 tednih metotreksat n = 110 n (%)
• including cancer of the lymph system (lymphoma) and 
• vključno z rakom limfnega sistema (limfomom) in;
p = 0.027, adalimumab 0.8 mg/kg versus MTX p = 0.083, adalimumab 0.8 mg/kg versus MTX 
PASI 75 PGA: čisto/minimalno p = 0,027, adalimumab 0,8 mg/kg v primerjavi z MTX p = 0,083, adalimumab 0,8 mg/kg v primerjavi z MTX
Time to Treatment Failure At or After Week 2 in Study UV II 
Čas do neuspeha zdravljenja v ali po 2. tednu v študiji UV II
If something goes wrong with the injection, do not use another Cyltezo pre-filled syringe. 
Če injiciranje ne poteka tako, kot bi bilo treba, ne uporabite drugega zdravila Cyltezo napolnjena injekcijska brizga.
Some of these hepatosplenic T-cell lymphomas with adalimumab have occurred in young adult patients on concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. 
Pri uporabi adalimumaba so se nekateri od hepatospleničnih T-celičnih limfomov pojavili pri mladih odraslih bolnikih, ki so se sočasno zdravili z azatioprinom ali 6-merkaptopurinom, ki se uporabljata pri vnetni bolezni črevesa.
Amongst those who responded at week 16 (n = 144), the Pediatric ACR 30/50/70/90 responses were maintained for up to six years in the OLE phase in patients who received adalimumab throughout the study. 
Med bolniki, ki so se odzvali 16. teden (n = 144), so se odzivi "Pediatric ACR" 30/50/70/90 v odprti podaljšani fazi ohranili do 6 let pri tistih, ki so ves čas študije dobivali adalimumab.
Kaplan-Meier Curves Summarizing Time to Flare in Study nr-axSpA II 
Kaplan-Meier-jeve krivulje povzemajo čas do ponovnega zagona bolezni v študiji nr-axSpA II
Patients who achieved sustained remission for at least 12 weeks (N = 305) (ASDAS < 1.3 at weeks 16, 20, 24, and 28) during the open-label period were then randomised to receive either continued treatment with adalimumab 40 mg eow (N = 152) or placebo (N = 153) for an additional 40 weeks in a double-blind, placebo-controlled period (total study duration 68 weeks). 
Bolniki, ki so v odprti fazi dosegli trajno remisijo za vsaj 12 tednov (N = 305) (ASDAS < 1,3 v 16., 20., 24. in 28. tednu), so bili nato randomizirani tako, da so prejemali bodisi nadaljevalno zdravljenje z adalimumabom 40 mg vsak drugi teden (N = 152) ali placebo (N = 153) dodatnih 40 tednov v dvojno slepem, s placebom kontroliranem obdobju (celotno trajanje študije 68 tednov).
It is important that you tell your baby's doctors and other health care professionals about your Cyltezo use during your pregnancy so they can decide when your 
Zato je pomembno, da obvestite zdravnika vašega otroka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Cyltezo, da se lahko odločijo, kdaj bo vaš otrok lahko prejel katero koli cepivo.
All patients received a 2-week standardised dose of prednisone 60 mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid discontinuation by 
Vsi bolniki so ob začetku študije prejeli 2-tedenski standardizirani odmerek prednizolona 60 mg/dan, čemur je sledil obvezen program postopnega zmanjševanja, s popolno ukinitvijo kortikosteroidov do 15. tedna.
• It is normal to see an air bubble. 
• Prisotnost zračnega mehurčka je normalna.
In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the adalimumab treated patients and 1.46 per patient year in the placebo and active control-treated patients. 
V ključnih kontroliranih preskušanjih pri odraslih in otrocih je bil delež okužb 1,51 na bolnikov-let med bolniki, ki so dobivali adalimumab, in 1,46 na bolnikov-let med bolniki, ki so dobivali placebo oziroma kontrolno učinkovino.
• If you have an infection, including long-term or localised infection (for example, leg ulcer) consult your doctor before starting Cyltezo. 
• Če imate kakšno okužbo, vključno z dolgotrajno ali omejeno okužbo (npr. razjedo na nogi), se pred uporabo zdravila Cyltezo posvetujte z zdravnikom.
Usually, Cyltezo is used with methotrexate. 
Zdravilo Cyltezo ponavadi uporabljamo z metotreksatom.
the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with 
▪ Zdravljenje hudega, aktivnega in progresivnega revmatoidnega artritisa pri odraslih, ki prej še
The syringe inside the pen is made from type I glass with a plunger stopper (butyl rubber) and a needle with a cap (outer part made of plastic material and inner part made of elastomer containing latex). 
Injekcijska igla znotraj peresnika je narejena iz stekla tipa I z batnim zamaškom (butilna guma) in igle s pokrovčkom (zunanji del je iz plastičnega materiala in notranji del iz elastomera, ki vsebuje lateks).
Adalimumab showed statistically significantly greater improvement in the HAQ-S total score and the SF-36 Physical Component Score (PCS) from baseline to week 12 compared to placebo. 
Adalimumab je pokazal statistično večje izboljšanje skupnega števila točk v HAQ-S vprašalniku in točk v telesno komponenti (PCS, Physical Component Score) v SF-36 vprašalniku od začetka do 12. tedna v primerjavi s placebom.
Based on the observed data approach, 222 (80.4 %) were in quiescence (no active inflammatory lesions, AC cell grade ≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg per day, and 184 (66.7 %) were in steroid-free quiescence. 
Na osnovi pristopa z opaženimi podatki je bilo 222 (80,4 %) bolnikov v remisiji (brez aktivnih vnetnih lezij, ocena celic sprednje očesne komore ≤ 0,5+, motnost steklovine ≤ 0,5+) ob sočasnem jemanju steroidov v odmerku ≤ 7,5 mg na dan in pa 184 bolnikov (66,7 %), ki so bili v remisiji in brez steroidov.
The 1 pre-filled pen pack comes with 2 alcohol pads (1 spare). 
Pakiranju z 1 napolnjenim injekcijskim peresnikom sta priložena 2 alkoholna zloženca (1 dodatni).
Induction of Clinical Remission and Response (Percent of Patients) 
Preglednica 24: Vzdrževanje klinične remisije in odziva (odstotek bolnikov)
The safety profile for patients with HS treated with adalimumab weekly was consistent with the known 
Varnostni profil bolnikov s HS, ki so bili tedensko zdravljeni z adalimumabom, je v skladu z znanim
If you develop a fever that does not go away, or you bruise or bleed very easily or look very pale, call your doctor right away. 
Če dobite zvišano telesno temperaturo, ki ne mine, če se vam pojavljajo podplutbe, zlahka zakrvavite ali ste zelo bledi, se takoj posvetujte z zdravnikom.
p value for Standard Dose versus Low Dose comparison. 
Vrednost p za primerjavo standardnega odmerka v primerjavi z majhnim odmerkom.
Seventy-nine (20.1 %) patients were treated concomitantly with disease modifying anti-rheumatic drugs, and 37 (9.4 %) patients with glucocorticoids. 
Devetinsedemdeset (20,1 %) bolnikov je sočasno dobivalo imunomodulacijska antirevmatična zdravila, 37 (9,4 %) bolnikov pa glukokortikoide.
The apparent adalimumab plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was 3 µg/mL 
Navidezna koncentracija adalimumaba v plazmi, ki doseže polovico največje verjetnosti PedACR 50 odziva (EC50) je bila 3 μg/ml (95% IZ: 1-6 μg/ml).
673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an inadequate response to ≥ 2 NSAIDs, or an intolerance to or a contraindication for NSAIDs enrolled into the open-label period of Study nr-axSpA II during which they received adalimumab 40 mg eow for 28 weeks. 
673 bolnikov z aktivnim nr-axSpA (srednja vrednost aktivnosti bolezni [BASDAI] je bila 7,0), ki so imeli nezadosten odgovor na vsaj dva NSAID ali niso prenašali NSAID ali s kontraindikacijo za NSAID, je bilo vključenih v odprto fazo študije nr-axSpA II, v kateri so prejemali adalimumab 40 mg vsak drugi teden 28 tednov.
Adalimumab in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). 
Adalimumab je v kombinaciji z metotreksatom indiciran za zdravljenje aktivnega poliartikularnega juvenilnega idiopatskega artritisa pri bolnikih od 2. leta starosti, ki se ne odzovejo ustrezno na eno ali več imunomodulirajočih antirevmatičnih zdravil.
A patient who requires surgery while on Cyltezo should be closely monitored for infections, and appropriate actions should be taken. 
Bolnika, ki med zdravljenjem z zdravilom Cyltezo potrebuje operacijo, je treba natančno nadzirati glede okužb in ustrezno ukrepati.
The air bubble does not need to be removed prior to injection. 
Pred injiciranjem zračnega mehurčka ni treba
For patients who stayed on their randomised therapy, the mean (± SD) adalimumab trough concentrations at week 52 were 9.5 ± 5.6 μg/mL for the Standard Dose group and 3.5 ± 2.2 μg/mL for the Low Dose group. 
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile srednje najmanjše koncentracije adalimumaba v 52. tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
Across all treatment groups, the mean baseline PASI score was 18.9 and the baseline Physician's Global Assessment (PGA) score ranged from “moderate” (53 % of subjects included) to “severe” (41 %) to “very severe” (6 %). 
V vseh terapevtskih skupinah je bila povprečna izhodiščna ocena PASI 18,9, izhodiščna zdravnikova globalna ocena (PGA, Physician's Global Assessment) pa je segala od "zmerne" (53 % vključenih preiskovancev) do "hude" (41 %) in "zelo hude" (6 %).
Physicians should exercise caution when considering the use of Cyltezo in patients with a history of recurring infection or with underlying conditions which may predispose patients to infections, including the use of concomitant immunosuppressive medications. 
Pri odločanju za uporabo zdravila Cyltezo je potrebna previdnost pri bolnikih z anamnezo ponavljajoče se okužbe ali z osnovnimi boleznimi, ki lahko zvečajo nagnjenost k okužbam, vključno s sočasno uporabljenimi imunosupresivnimi zdravili.
RA Study III a** 
Študija revmatoidnega artritisa I a**
The primary endpoint was the percent change from Baseline to week 12 in the number of active joints with arthritis (swelling not due to deformity or joints with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of -62.6 % (median percent change -88.9 %) in patients in the adalimumab group compared to -11.6 % (median percent change -50.0 %) in patients in the placebo group. 
Primarni opazovani dogodek je bil odstotek spremembe od izhodiščne vrednosti do 12. tedna v številu aktivnih sklepov z artritisom (oteklina, ki ni nastala zaradi deformacije ali sklepi z zmanjšano gibljivostjo ter bolečino in/ali občutljivostjo); slednji je bil dosežen s povprečnim odstotnim zmanjšanjem za -62,6 % (mediana odstotna sprememba -88,9 %) pri skupini bolnikov, ki je prejemala adalimumab v primerjavi z -11,6 % (mediana odstotna sprememba -50,0 %) v skupini bolnikov, ki je prejemala placebo.
• Cyltezo can be used during breast-feeding. 
• Zdravilo Cyltezo se lahko uporablja med dojenjem.
Any unused medicinal product or waste material should be disposed of in accordance with local 
6.6 Posebni varnostni ukrepi za odstranjevanje Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
• Remove cap by pulling it straight off pen. 
• Pokrovček odstranite tako, da ga povlečete naravnost dol s peresnika.
• Do not attempt to reuse a used Cyltezo pen. 
• Uporabljenega peresnika z zdravilom Cyltezo ne uporabite znova.
• Do not use the 40 mg pre-filled syringe, if doses other than 40 mg are recommended. 
• Ne uporabljajte 40 mg napolnjene injekcijske brizge, če so priporočeni drugi odmerki kot
Cyltezo can also be used to treat severe, active and progressive rheumatoid arthritis without previous 
Zdravilo Cyltezo je mogoče uporabljati tudi za zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa brez predhodnega zdravljenja z metotreksatom.
If adequate response is achieved with 40 mg every week or 80 mg every other week, the dosage may subsequently be reduced to 40 mg every other 
Če je dosežen zadosten odziv na zdravljenje s 40 mg vsak teden ali 80 mg vsak drugi teden , se lahko odmerek pozneje zmanjša na 40 mg vsak drugi teden.
For the 2, 4 and 6 pre-filled pen packs, each pre-filled pen comes with 1 alcohol pad. 
V pakiranjih z 2, 4 in 6 napolnjenimi injekcijskimi peresniki pa je vsakemu napolnjenemu injekcijskemu peresniku priložen 1 alkoholni zloženec.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor) while on Cyltezo. 
Vsem bolnikom je treba naročiti, naj nemudoma poiščejo zdravniško pomoč, če se jim med uporabo zdravila Cyltezo pojavijo znaki ali simptomi krvnih diskrazij (npr. trajno zvišana telesna temperatura, podplutbe, krvavitve, bledica).
In the Phase 3 trial of adalimumab in patients with paediatric Crohn's disease which evaluated efficacy and safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction therapy up to 52 weeks of treatment, ALT elevations ≥ 3 x ULN occurred in 2.6 % (5/192) of patients of whom 4 were receiving concomitant immunosuppressants at baseline. 
V preskušanju faze 3 z adalimumabom pri bolnikih s pediatrično Crohnovo boleznijo, kjer so ocenjevali učinkovitost in varnost dveh telesni masi prilagojenih vzdrževalnih režimov odmerjanja, ki sta sledila telesni masi prilagojenemu začetnemu zdravljenju do 52 tednov zdravljenja, so se pojavila zvišanja ALT ≥ 3 x ULN pri 2,6 % (5/192) bolnikov, od katerih so štirje sočasno prejemali imunosupresive ob začetku preskušanja.